Vasopressin Injection, USP

Manufacturer
Fresenius Kabi USA, LLC
Effective date
2019-12-30
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
4
Source
legacy-cache
Hydrated at
2026-08-01 23:47:46

Label at a glance#

ProductVasopressin
Active ingredientVASOPRESSIN
Label structure12 sections

Indications and uses

Vasopressin Injection, USP is indicated for prevention and treatment of postoperative abdominal distention, in abdominal roentgenography to dispel interfering gas shadows and in diabetes insipidus.

Dosage and administration

Vasopressin Injection may be administered IM or subcutaneously. Ten units (0.5 mL) of Vasopressin Injection will usually elicit full physiologic response in adult patients; 5 units (0.25 mL) will be adequate in many cases.  Vasopressin Injection should be given IM at three or four hour intervals as needed.  The dosage should be proportionately reduced for pediatric patients.  (For an additional discussion of dosag...

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

(SYNTHETIC)

DESCRIPTION

DESCRIPTION SECTION

Vasopressin Injection, USP is a sterile solution of synthetic vasopressin of the posterior pituitary gland for intramuscular (IM) or subcutaneous use.  It is substantially free from the oxytocic principle and is standardized to contain 20 pressor units/mL.  The chemical name is Vasopressin, 8-L-arginine and has the following structural formula:

  

vass-struvass-stru

 

C46H65N15O12S2                                        1084.23

Each mL contains: 20 USP Vasopressin Units, chlorobutanol (anhydrous) 5 mg as preservative; Water for Injection q.s.  Glacial acetic acid and/or sodium hydroxide may have been added for pH adjustment (2.5-4.5).

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

The antidiuretic action of vasopressin is ascribed to increasing reabsorption of water by the renal tubules.

Vasopressin can cause contraction of smooth muscle of the gastrointestinal tract and of all parts of the vascular bed, especially the capillaries, small arterioles and venules with less effect on the smooth musculature of the large veins.  The direct effect on the contractile elements is neither antagonized by adrenergic blocking agents nor prevented by vascular denervation.

Following subcutaneous or intramuscular administration of vasopressin injection, the duration of antidiuretic activity is variable but effects are usually maintained for 2 to 8 hours.

The majority of a dose of vasopressin is metabolized and rapidly destroyed in the liver and kidneys.  Vasopressin has a plasma half-life of about 10 to 20 minutes.  Approximately 5% of a subcutaneous dose of vasopressin is excreted in urine unchanged after 4 hours.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Vasopressin Injection, USP is indicated for prevention and treatment of postoperative abdominal distention, in abdominal roentgenography to dispel interfering gas shadows and in diabetes insipidus.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Anaphylaxis or hypersensitivity to the drug or its components.

WARNINGS

WARNINGS SECTION

This drug should not be used in patients with vascular disease, especially disease of the coronary arteries, except with extreme caution.  In such patients, even small doses may precipitate anginal pain, and with larger doses, the possibility of myocardial infarction should be considered.

Vasopressin may produce water intoxication.  The early signs of drowsiness, listlessness and headaches should be recognized to prevent terminal coma and convulsions.

PRECAUTIONS

PRECAUTIONS SECTION

General

PRECAUTIONS SECTION

Vasopressin should be used cautiously in the presence of epilepsy, migraine, asthma, heart failure or any state in which a rapid addition to extracellular water may produce hazard for an already overburdened system.

Chronic nephritis with nitrogen retention contraindicates the use of vasopressin until reasonable nitrogen blood levels have been attained.

Information for Patients

PRECAUTIONS SECTION

Side effects such as blanching of skin, abdominal cramps, and nausea may be reduced by taking 1 or 2 glasses of water at the time of vasopressin administration.  These side effects are usually not serious and probably will disappear within a few minutes.

Laboratory Tests

PRECAUTIONS SECTION

Electrocardiograms (ECG) and fluid and electrolyte status determinations are recommended at periodic intervals during therapy.

Drug Interactions

PRECAUTIONS SECTION

The following drugs may potentiate the antidiuretic effect of vasopressin when used concurrently: carbamazepine; chlorpropamide; clofibrate; urea; fludrocortisone; tricyclic antidepressants.

The following drugs may decrease the antidiuretic effect of vasopressin when used concurrently: demeclocycline; norepinephrine; lithium; heparin; alcohol.

Ganglionic blocking agents may produce a marked increase in sensitivity to the pressor effects of vasopressin.

Pregnancy Category C

PRECAUTIONS SECTION

Animal reproduction studies have not been conducted with vasopressin.  It is also not known whether vasopressin can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.  Vasopressin should be given to a pregnant woman only if clearly needed.

Labor and Delivery

PRECAUTIONS SECTION

Doses of vasopressin sufficient for an antidiuretic effect are not likely to produce tonic uterine contractions that could be deleterious to the fetus or threaten the continuation of the pregnancy.

Nursing Mothers

PRECAUTIONS SECTION

Caution should be exercised when vasopressin is administered to a nursing woman.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Local or systemic allergic reactions may occur in hypersensitive individuals.  The following side effects have been reported following the administration of vasopressin:

Body as a Whole

ADVERSE REACTIONS SECTION

Anaphylaxis (cardiac arrest and/or shock) has been observed shortly after injection of vasopressin.

Cardiovascular

ADVERSE REACTIONS SECTION

Cardiac arrest, circumoral pallor, arrhythmias, decreased cardiac output, angina, myocardial ischemia, peripheral vasoconstriction, and gangrene.

Gastrointestinal

ADVERSE REACTIONS SECTION

Abdominal cramps, nausea, vomiting, passage of gas.

Nervous System

ADVERSE REACTIONS SECTION

Tremor, vertigo, ‘‘pounding’’ in head.

Respiratory

ADVERSE REACTIONS SECTION

Bronchial constriction.

Skin and Appendages

ADVERSE REACTIONS SECTION

Sweating, urticaria, cutaneous gangrene.

Overdosage

ADVERSE REACTIONS SECTION

Water intoxication may be treated with water restriction and temporary withdrawal of vasopressin until polyuria occurs. Severe water intoxication may require osmotic diuresis with mannitol, hypertonic dextrose, or urea alone or with furosemide.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Vasopressin Injection may be administered IM or subcutaneously.

Ten units (0.5 mL) of Vasopressin Injection will usually elicit full physiologic response in adult patients; 5 units (0.25 mL) will be adequate in many cases.  Vasopressin Injection should be given IM at three or four hour intervals as needed.  The dosage should be proportionately reduced for pediatric patients.  (For an additional discussion of dosage, consult the sections below.)

When determining the dose of Vasopressin Injection for a given case, the following should be kept in mind:

It is particularly desirable to give a dose not much larger than is just sufficient to elicit the desired physiologic response.  Excessive doses may cause undesirable side effects–blanching of the skin, abdominal cramps, nausea–which, though not serious, may be alarming to the patient.  Spontaneous recovery from such side effects occurs in a few minutes.  It has been found that one or two glasses of water given at the time Vasopressin Injection is administered reduces such symptoms.

Abdominal Distention

DOSAGE & ADMINISTRATION SECTION

In the average postoperative adult patient, give 5 units (0.25 mL) initially, increase to 10 units (0.5 mL) at subsequent injections if necessary.  It is recommended that Vasopressin Injection be given IM and that injections be repeated at three or four hour intervals as required.  Dosage to be reduced proportionately for pediatric patients.

Vasopressin Injection used in this manner will frequently prevent, or relieve, postoperative distention.  These recommendations apply also to distention complicating pneumonia or other acute toxemias.

Abdominal Roentgenography

DOSAGE & ADMINISTRATION SECTION

For the average case, two injections of 10 units (0.5 mL) each are suggested.  These should be given two hours and one-half hour, respectively, before films are exposed.  Many roentgenologists advise giving an enema prior to the first dose of Vasopressin Injection.

Diabetes Insipidus

DOSAGE & ADMINISTRATION SECTION

Vasopressin Injection may be given by injection or administered intranasally on cotton pledgets, by nasal spray, or by dropper.  The dose by injection is 5 to 10 units (0.25 to 0.5 mL) repeated two or three times daily as needed.  When Vasopressin Injection is administered intranasally by spray or on pledgets, the dosage and interval between treatments must be determined for each patient.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

HOW SUPPLIED

HOW SUPPLIED SECTION

Product

No.

NDC

No.


30201       

63323-302-01   

Vasopressin Injection, USP 20 units, 1 mL fill in a 2 mL flip-top vial in packages of 25.

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

Do not freeze.

This container closure is not made with natural rubber latex.

SPL UNCLASSIFIED SECTION

logo
logo

45875F

Revised: September 2013

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

PACKAGE LABEL - PRINCIPAL DISPLAY - Vasopressin 1 mL Vial Label

NDC 63323-302-01

30201

Vasopressin Injection, USP  (Synthetic)

20 Units/mL

For IM or SC Use

1 mL

Sterile

Rx only

30201-vial
30201-vial

PACKAGE LABEL - PRINCIPAL DISPLAY - Vasopressin 1 mL Vial Tray Label

NDC 63323-302-01

30201

Vasopressin Injection, USP  (Synthetic)

20 Units/mL

For IM or SC Use

1 mL

Rx only

30201-tray30201-tray

 

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
63323-302-01ML - Milliliter63323-3020bd962b8-76a9-4123-83a7-c6bb8cf4d72812013-02-13
63323-302-09ML - Milliliter63323-302de278d0a-71fe-4623-9eaa-0b9aef5c5e8212014-08-01

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
VASOPRESSINACTIVE INGREDIENTY87Y826H082
VASOPRESSINACTIVE MOIETYY87Y826H082
ACETIC ACIDINACTIVE INGREDIENTQ40Q9N063P2
CHLOROBUTANOLINACTIVE INGREDIENTHM4YQM8WRC2
SODIUM HYDROXIDEINACTIVE INGREDIENT55X04QC32I2

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 4 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
63323-30263323-302-01

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 4 matching rows.

Source Document#

Source XML · Source PDF

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 4 · 235 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, FOR SOLUTION / PARENTERALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION/ DROPS / AURICULAR (OTIC)ADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
ACETIC ACIDACETIC ACIDQ40Q9N063PINJECTION / SUBCUTANEOUS22 mgExact identifier — unii candidate
45 equally ranked IID candidates
CHLOROBUTANOLCHLOROBUTANOLHM4YQM8WRCTABLET / ORALNAExact identifier — unii candidate
16 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / SUBCUTANEOUSADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IFILM, SOLUBLE / ORAL11 mgExact identifier — unii candidate
174 equally ranked IID candidates
CHLOROBUTANOLCHLOROBUTANOLHM4YQM8WRCSOLUTION / NASAL5.25 mg/1mlExact identifier — unii candidate
16 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAMUSCULAR0.35 %w/vExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IEMULSION / OPHTHALMIC0.02 %w/vExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / INTRATHECALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, FOR SUSPENSION / INTRAVENOUSADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SUSPENSION / INTRAVITREALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / INTRATUMORADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
ACETIC ACIDACETIC ACIDQ40Q9N063PINJECTION / INTRAVENOUS827 mgExact identifier — unii candidate
45 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ICAPSULE, DELAYED RELEASE / ORAL0.25 mgExact identifier — unii candidate
174 equally ranked IID candidates
CHLOROBUTANOLCHLOROBUTANOLHM4YQM8WRCSPRAY, METERED / NASAL20 mgExact identifier — unii candidate
16 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IJELLY / TOPICALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ILOTION / TOPICAL21 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IAEROSOL, METERED / RESPIRATORY (INHALATION)ADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
CHLOROBUTANOLCHLOROBUTANOLHM4YQM8WRCSOLUTION / RESPIRATORY (INHALATION)0.5 %w/wExact identifier — unii candidate
16 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR7.01 mgExact identifier — unii candidate
174 equally ranked IID candidates
ACETIC ACIDACETIC ACIDQ40Q9N063PAEROSOL, FOAM / VAGINAL0.03 %w/wExact identifier — unii candidate
45 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISYRUP / ORAL71 mg/5mlExact identifier — unii candidate
174 equally ranked IID candidates
ACETIC ACIDACETIC ACIDQ40Q9N063PCAPSULE / ORALNAExact identifier — unii candidate
45 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / TOPICAL39 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / INTRACAUDALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / EPIDURALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / RECTALNAExact identifier — unii candidate
174 equally ranked IID candidates
ACETIC ACIDACETIC ACIDQ40Q9N063PINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAMUSCULARADJ PHExact identifier — unii candidate
45 equally ranked IID candidates
ACETIC ACIDACETIC ACIDQ40Q9N063PLIQUID / SUBCUTANEOUS0.2 %w/vExact identifier — unii candidate
45 equally ranked IID candidates
CHLOROBUTANOLCHLOROBUTANOLHM4YQM8WRCOINTMENT / OPHTHALMIC0.65 %w/wExact identifier — unii candidate
16 equally ranked IID candidates
ACETIC ACIDACETIC ACIDQ40Q9N063PINJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUSADJ PHExact identifier — unii candidate
45 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / PERIODONTALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
ACETIC ACIDACETIC ACIDQ40Q9N063PSPONGE / TOPICALADJ PHExact identifier — unii candidate
45 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IEMULSION / ORALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
CHLOROBUTANOLCHLOROBUTANOLHM4YQM8WRCSUSPENSION / INTRAMUSCULAR3.5 mgExact identifier — unii candidate
16 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SUSPENSION / SUBCUTANEOUSADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / SUBCUTANEOUS1 %w/vExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION/ DROPS / TOPICALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / INTRATHECALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
ACETIC ACIDACETIC ACIDQ40Q9N063PINJECTION, EMULSION / INTRAMUSCULARADJ PHExact identifier — unii candidate
45 equally ranked IID candidates
CHLOROBUTANOLCHLOROBUTANOLHM4YQM8WRCDROPS / NASAL500 mgExact identifier — unii candidate
16 equally ranked IID candidates
ACETIC ACIDACETIC ACIDQ40Q9N063PINJECTION, EMULSION / SUBCUTANEOUSADJ PHExact identifier — unii candidate
45 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / INTRAPERITONEALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ILIQUID / INTRAVENOUSADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISUSPENSION, EXTENDED RELEASE / INTRADERMALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / INTRA-ARTICULARADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / INTRAMUSCULAR78 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / INTRADERMALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IGEL / TOPICAL70 mgExact identifier — unii candidate
174 equally ranked IID candidates
ACETIC ACIDACETIC ACIDQ40Q9N063PINJECTION, POWDER, FOR SOLUTION / INTRAMUSCULARADJ PHExact identifier — unii candidate
45 equally ranked IID candidates
ACETIC ACIDACETIC ACIDQ40Q9N063PSYRUP / ORAL10 mgExact identifier — unii candidate
45 equally ranked IID candidates
ACETIC ACIDACETIC ACIDQ40Q9N063PSOLUTION / INTRAVENOUS14 mgExact identifier — unii candidate
45 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ITABLET, FILM COATED / ORAL8 mgExact identifier — unii candidate
174 equally ranked IID candidates
ACETIC ACIDACETIC ACIDQ40Q9N063PINJECTION, SOLUTION / INTRAVENOUS15 mgExact identifier — unii candidate
45 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR5.4 mgExact identifier — unii candidate
174 equally ranked IID candidates
ACETIC ACIDACETIC ACIDQ40Q9N063PCREAM / TOPICALNAExact identifier — unii candidate
45 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / INTRA-ARTERIALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
ACETIC ACIDACETIC ACIDQ40Q9N063PINJECTION, SOLUTION / SUBMUCOSALADJ PHExact identifier — unii candidate
45 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / INTRAOCULARADJ PHExact identifier — unii candidate
174 equally ranked IID candidates

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
a97bc3b8-2641-5fcd-e053-2995a90ae9a9fa461271-91e8-4a83-8435-5f52040ab41b2020-07-02Warnings, Adverse reactionsExact identifier
spl set id: fa461271-91e8-4a83-8435-5f52040ab41b

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.